DSM Capital Partners LLC Has $125.29 Million Holdings in DexCom, Inc. $DXCM

DSM Capital Partners LLC grew its position in DexCom, Inc. (NASDAQ:DXCM) by 252.1% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,435,296 shares of the medical device company’s stock after purchasing an additional 1,027,633 shares during the quarter. DexCom comprises approximately 1.9% of DSM Capital Partners LLC’s investment portfolio, making the stock its 17th biggest position. DSM Capital Partners LLC owned about 0.37% of DexCom worth $125,287,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. SWS Partners acquired a new position in shares of DexCom in the second quarter valued at approximately $1,661,000. Baader Bank Aktiengesellschaft acquired a new position in shares of DexCom in the second quarter valued at approximately $393,000. Assenagon Asset Management S.A. grew its position in shares of DexCom by 85.7% in the second quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after purchasing an additional 557,576 shares during the last quarter. Mn Services Vermogensbeheer B.V. grew its position in shares of DexCom by 4.9% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after purchasing an additional 6,800 shares during the last quarter. Finally, Shell Asset Management Co. grew its position in shares of DexCom by 16.8% in the second quarter. Shell Asset Management Co. now owns 35,812 shares of the medical device company’s stock valued at $3,126,000 after purchasing an additional 5,138 shares during the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the company’s stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $80.00, for a total transaction of $117,280.00. Following the completion of the sale, the executive vice president directly owned 105,223 shares in the company, valued at $8,417,840. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares of the company’s stock, valued at $4,143,868.26. The trade was a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock valued at $564,733 over the last ninety days. Company insiders own 0.32% of the company’s stock.

Analysts Set New Price Targets

DXCM has been the topic of several research reports. Wall Street Zen downgraded DexCom from a “strong-buy” rating to a “buy” rating in a research report on Sunday, August 10th. Morgan Stanley increased their price target on DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 15th. Citigroup reduced their price target on DexCom from $105.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday. Raymond James Financial increased their price target on DexCom from $99.00 to $102.00 and gave the stock a “strong-buy” rating in a research report on Thursday, July 31st. Finally, Argus began coverage on DexCom in a research report on Thursday, August 21st. They set a “buy” rating and a $100.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $97.42.

DexCom Stock Down 4.3%

NASDAQ DXCM opened at $65.12 on Friday. The business has a fifty day moving average price of $74.42 and a two-hundred day moving average price of $77.62. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $93.25. The stock has a market capitalization of $25.54 billion, a PE ratio of 45.22, a PEG ratio of 1.43 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last released its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same period in the prior year, the company earned $0.43 earnings per share. The company’s quarterly revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Equities analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.